About Evolent Health (NYSE:EVH)
Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management. Its services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services, and comprehensive health plan administration services. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
Industry, Sector and Symbol
Industry Management services
Sub-IndustryN/A
SectorComputer and Technology
SymbolNYSE:EVH
CUSIPN/A
Phone571-389-6000
Debt
Debt-to-Equity Ratio0.12%
Current Ratio2.85%
Quick Ratio2.85%
Price-To-Earnings
Trailing P/E Ratio-23.79
Forward P/E Ratio-48.97
P/E GrowthN/A
Sales & Book Value
Annual Sales$434.95 million
Price / Sales2.96
Cash FlowN/A
Price / CashN/A
Book Value$13.52 per share
Price / Book1.23
Profitability
EPS (Most Recent Fiscal Year)($0.70)
Net Income$-60,660,000.00
Net Margins-14.05%
Return on Equity-3.51%
Return on Assets-2.79%
Miscellaneous
Employees2,600
Outstanding Shares77,440,000
Evolent Health (NYSE:EVH) Frequently Asked Questions
What is Evolent Health's stock symbol?
Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."
How were Evolent Health's earnings last quarter?
Evolent Health (NYSE:EVH) issued its quarterly earnings results on Tuesday, February, 27th. The technology company reported ($0.10) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.10). The technology company earned $113.97 million during the quarter, compared to analysts' expectations of $111.09 million. Evolent Health had a negative net margin of 14.05% and a negative return on equity of 3.51%. View Evolent Health's Earnings History.
What price target have analysts set for EVH?
12 brokers have issued 12-month target prices for Evolent Health's stock. Their predictions range from $17.00 to $30.00. On average, they expect Evolent Health's share price to reach $24.50 in the next twelve months. View Analyst Ratings for Evolent Health.
What are Wall Street analysts saying about Evolent Health stock?
Here are some recent quotes from research analysts about Evolent Health stock:
- 1. According to Zacks Investment Research, "Evolent Health, Inc. is involved in the healthcare delivery and payment markets. The company provides technology-enabled services platform for providers to transition their organization in value-based payment models. Evolent Health, Inc. is based in Arlington, Virginia. " (3/8/2018)
- 2. Cantor Fitzgerald analysts commented, "Health plan acquisitions. Over the past few months, EVH has announced two small health plan acquisitions that should help to grow its platform and operations revenue and add a new line of business. The acquisition of Premier in Dayton, OH, is somewhat more concerning for investors as the regulatory filings show that the plan is in a loss position. However, many provider-owned health plans typically show losses in regulatory filings. The company is expecting to receive better pricing from Premier and that it is not considering additional health plan acquisitions, at least in the near term. However, it will continue to use capital to align the company with customers. Note, our estimates do not yet reflect the health plan acquisitions." (12/3/2017)
Who are some of Evolent Health's key competitors?
Who are Evolent Health's key executives?
Evolent Health's management team includes the folowing people:
- Mr. Frank J. Williams, Co-Founder, CEO & Director (Age 51)
- Mr. Seth Blackley, Co-Founder & Pres (Age 39)
- Mr. Steven J. Wigginton, Former Exec. VP (Age 52)
- Mr. Tom Peterson III, Co-Founder & COO (Age 48)
- Mr. Nicholas McGrane, Chief Financial Officer (Age 50)
When did Evolent Health IPO?
(EVH) raised $150 million in an IPO on Friday, June 5th 2015. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.
Has Evolent Health been receiving favorable news coverage?
Media coverage about EVH stock has trended somewhat positive on Tuesday, according to Accern Sentiment. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Evolent Health earned a coverage optimism score of 0.13 on Accern's scale. They also assigned news stories about the technology company an impact score of 49.30 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Evolent Health?
Shares of EVH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Evolent Health's stock price today?
One share of EVH stock can currently be purchased for approximately $16.65.
How big of a company is Evolent Health?
Evolent Health has a market capitalization of $1.30 billion and generates $434.95 million in revenue each year. The technology company earns $-60,660,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Evolent Health employs 2,600 workers across the globe.
How can I contact Evolent Health?
Evolent Health's mailing address is 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203. The technology company can be reached via phone at 571-389-6000.
MarketBeat Community Rating for Evolent Health (EVH)
MarketBeat's community ratings are surveys of what our community members think about Evolent Health and other stocks. Vote "Outperform" if you believe EVH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Evolent Health (NYSE:EVH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
12 Wall Street analysts have issued ratings and price targets for Evolent Health in the last 12 months. Their average twelve-month price target is $24.50, suggesting that the stock has a possible upside of 47.15%. The high price target for EVH is $30.00 and the low price target for EVH is $17.00. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.92 | 3.00 | 3.00 | 3.08 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $24.50 | $25.3333 | $28.00 | $28.4545 |
| Price Target Upside: | 47.15% upside | 72.92% upside | 108.96% upside | 56.77% upside |
Evolent Health (NYSE:EVH) Consensus Price Target History
Evolent Health (NYSE:EVH) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Evolent Health (NYSE:EVH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Evolent Health (NYSE EVH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.79%
Institutional Ownership Percentage: 99.71%
Evolent Health (NYSE EVH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/1/2018 | Unitedhealth Group Inc | Director | Sell | 3,040,000 | $13.70 | $41,648,000.00 | |  |
| 8/3/2017 | Frank J. Williams | CEO | Sell | 16,300 | $23.73 | $386,799.00 | | |
| 8/1/2017 | Steve Wigginton | CEO | Sell | 6,000 | $24.64 | $147,840.00 | | |
| 7/24/2017 | Thomas Peterson III | COO | Sell | 40,540 | $26.00 | $1,054,040.00 | | |
| 7/10/2017 | Nicholas Mcgrane | CFO | Sell | 1,667 | $25.42 | $42,375.14 | | |
| 7/6/2017 | Frank J. Williams | CEO | Sell | 16,300 | $24.76 | $403,588.00 | | |
| 7/3/2017 | Steve Wigginton | CEO | Sell | 6,000 | $25.07 | $150,420.00 | | |
| 6/28/2017 | Tpg Growth Ii Advisors, Inc. | Insider | Sell | 4,279,325 | $25.87 | $110,706,137.75 | | |
| 6/15/2017 | Seth Blackley | President | Sell | 15,000 | $25.22 | $378,300.00 | | |
| 6/12/2017 | Nicholas Mcgrane | CFO | Sell | 1,667 | $24.58 | $40,974.86 | | |
| 6/7/2017 | Nicholas Mcgrane | CFO | Sell | 10,495 | $26.95 | $282,840.25 | | |
| 6/6/2017 | Kenneth A. Samet | Director | Sell | 4,000 | $25.75 | $103,000.00 | | |
| 6/6/2017 | Steve Wigginton | CEO | Sell | 959 | $25.75 | $24,694.25 | | |
| 5/19/2017 | Cheryl Scott | Director | Sell | 5,477 | $23.51 | $128,764.27 | | |
| 5/19/2017 | Frank J. Williams | CEO | Sell | 114,865 | $24.30 | $2,791,219.50 | | |
| 5/19/2017 | Jonathan Weinberg | General Counsel | Sell | 17,230 | $24.30 | $418,689.00 | | |
| 5/19/2017 | Nicholas Mcgrane | CFO | Sell | 47,508 | $24.30 | $1,154,444.40 | | |
| 5/19/2017 | Thomas Peterson III | COO | Sell | 57,433 | $24.30 | $1,395,621.90 | | |
| 5/19/2017 | Tpg Growth Ii Advisors, Inc. | Insider | Sell | 3,081,760 | $24.30 | $74,886,768.00 | | |
| 5/19/2017 | Upmc | Major Shareholder | Sell | 2,333,333 | $24.30 | $56,699,991.90 | 6,434,283 | |
| 5/15/2017 | Seth Blackley | President | Sell | 15,000 | $25.00 | $375,000.00 | 760,944 | |
| 5/15/2017 | Thomas Peterson III | COO | Sell | 83,108 | $24.99 | $2,076,868.92 | 341,092 | |
| 5/10/2017 | Nicholas Mcgrane | Insider | Sell | 1,667 | $24.28 | $40,474.76 | 132,047 | |
| 5/10/2017 | Thomas Peterson III | COO | Sell | 18,604 | $25.00 | $465,100.00 | 395,587 | |
| 5/4/2017 | Frank J Williams | CEO | Sell | 16,300 | $23.55 | $383,865.00 | 1,284,943 | |
| 5/3/2017 | Jonathan Weinberg | General Counsel | Sell | 15,000 | $23.85 | $357,750.00 | 86,385 | |
| 5/1/2017 | Steve Wigginton | CEO | Sell | 6,000 | $23.10 | $138,600.00 | 364,704 | |
| 5/1/2017 | Upmc | Major Shareholder | Sell | 403,644 | $19.53 | $7,883,167.32 | 8,767,616 | |
| 4/19/2017 | Nicholas Mcgrane | CFO | Sell | 1,667 | $22.52 | $37,540.84 | 132,047 | |
| 4/17/2017 | Seth Blackley | President | Sell | 15,000 | $21.48 | $322,200.00 | 794,602 | |
| 4/6/2017 | Frank J Williams | CEO | Sell | 16,300 | $22.03 | $359,089.00 | 1,301,243 | |
| 4/3/2017 | Steve Wigginton | CEO | Sell | 6,000 | $23.15 | $138,900.00 | 364,704 | |
| 3/31/2017 | Upmc | Major Shareholder | Sell | 2,690,961 | $19.53 | $52,554,468.33 | 9,171,260 | |
| 3/30/2017 | Seth Blackley | President | Sell | 15,000 | $21.19 | $317,850.00 | 807,228 | |
| 3/28/2017 | Board Co Advisory | Major Shareholder | Sell | 2,118,078 | $19.53 | $41,366,063.34 | 6,246,245 | |
| 3/24/2017 | Nicholas Mcgrane | CFO | Sell | 7,034 | $22.50 | $158,265.00 | 137,414 | |
| 1/30/2017 | Seth Blackley | President | Sell | 15,000 | $17.58 | $263,700.00 | 824,848 | |
| 1/17/2017 | Seth Blackley | President | Sell | 30,000 | $17.98 | $539,400.00 | 854,848 | |
| 11/14/2016 | Michael D'amato | Director | Buy | 10,000 | $17.18 | $171,800.00 | 18,183 | |
| 9/22/2016 | Board Co Advisory | Major Shareholder | Sell | 317,712 | $22.50 | $7,148,520.00 | 4,128,167 | |
| 9/14/2016 | Board Co Advisory | Major Shareholder | Sell | 1,936,529 | $22.50 | $43,571,902.50 | 4,445,879 | |
| 9/14/2016 | Chad Pomeroy | Insider | Sell | 55,180 | $21.54 | $1,188,577.20 | 286,370 | |
| 9/14/2016 | Frank J Williams | CEO | Sell | 251,481 | $21.54 | $5,416,900.74 | 1,304,799 | |
| 9/14/2016 | Jonathan Weinberg | General Counsel | Sell | 10,339 | $21.54 | $222,702.06 | 76,245 | |
| 9/14/2016 | Nicholas Mcgrane | CFO | Sell | 21,205 | $21.54 | $456,755.70 | 136,495 | |
| 9/14/2016 | Seth Blackley | President | Sell | 167,672 | $21.54 | $3,611,654.88 | 869,848 | |
| 9/14/2016 | Thomas Peterson III | COO | Sell | 72,827 | $21.54 | $1,568,693.58 | 377,623 | |
| 6/10/2015 | Gary Piefer | Insider | Buy | 2,000 | $17.00 | $34,000.00 | | |
(Data available from 1/1/2013 forward)
Evolent Health (NYSE EVH) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Evolent Health (EVH) Downgraded by JPMorgan Chase
www.americanbankingnews.com - April 24 at 8:28 AM |
 | Evolent Health, Inc. to Release First Quarter 2018 Operating Results and Host Conference Call on Wednesday, May 9, 2018
finance.yahoo.com - April 23 at 4:00 PM |
| Evolent Health (EVH) Downgraded by BidaskClub to "Buy"
www.americanbankingnews.com - April 16 at 10:25 AM |
| Evolent Health (EVH) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - April 15 at 10:59 AM |
| BidaskClub Lowers Evolent Health (EVH) to Hold
www.americanbankingnews.com - April 14 at 11:25 PM |
| ServiceMaster (SERV) and Evolent Health (EVH) Critical Survey
www.americanbankingnews.com - April 13 at 1:18 PM |
| Evolent Health (EVH) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 12 at 9:53 AM |
| Evolent Health (EVH) Earns Outperform Rating from Cowen
www.americanbankingnews.com - April 11 at 6:13 PM |
 | Somatus Raises $11 Million in Series B Financing
www.prnewswire.com - April 11 at 10:47 AM |
| $140.96 Million in Sales Expected for Evolent Health (EVH) This Quarter
www.americanbankingnews.com - April 11 at 2:05 AM |
| Evolent Health (EVH) Expected to Post Earnings of -$0.04 Per Share
www.americanbankingnews.com - April 9 at 7:19 PM |
| Contrasting Evolent Health (EVH) & FranklinCovey (FC)
www.americanbankingnews.com - April 7 at 1:25 PM |
| ValuEngine Lowers Evolent Health (EVH) to Strong Sell
www.americanbankingnews.com - April 3 at 4:16 PM |
| Evolent Health (EVH) Downgraded by Goldman Sachs to Buy
www.americanbankingnews.com - April 1 at 4:16 PM |
| Evolent Health (EVH) Receives New Coverage from Analysts at Citigroup
www.americanbankingnews.com - March 30 at 4:32 PM |
| Head-To-Head Survey: Evolent Health (EVH) & QuinStreet (QNST)
www.americanbankingnews.com - March 26 at 5:28 AM |
| Evolent Health Inc (EVH) Expected to Announce Quarterly Sales of $140.96 Million
www.americanbankingnews.com - March 25 at 2:52 AM |
| Analysts Expect Evolent Health Inc (EVH) to Announce -$0.04 Earnings Per Share
www.americanbankingnews.com - March 23 at 7:26 PM |
| NQ Mobile (LKM) vs. Evolent Health (EVH) Financial Analysis
www.americanbankingnews.com - March 21 at 9:12 PM |
| Evolent Health Supports Ten ACOs Accepted to Next Generation ACO Program for 2018 Performance Year
finance.yahoo.com - March 20 at 4:11 PM |
| Evolent Health Inc (EVH) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 18 at 10:20 AM |
| Evolent Health (EVH) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 8 at 9:58 PM |
| Zacks: Brokerages Anticipate Evolent Health Inc (EVH) Will Announce Quarterly Sales of $140.94 Million
www.americanbankingnews.com - March 8 at 3:48 AM |
| Evolent Health Inc (EVH) Director Sells $41,648,000.00 in Stock
www.americanbankingnews.com - March 5 at 6:22 PM |
| Evolent Health Inc (EVH) Stake Decreased by Sectoral Asset Management Inc
www.americanbankingnews.com - March 5 at 4:06 PM |
| State of Wisconsin Investment Board Buys Shares of 400,000 Evolent Health Inc (EVH)
www.americanbankingnews.com - March 2 at 7:50 PM |
| Lombard Odier Asset Management USA Corp Has $4.67 Million Position in Evolent Health Inc (EVH)
www.americanbankingnews.com - March 2 at 6:16 PM |
| Cortina Asset Management LLC Buys 125,053 Shares of Evolent Health Inc (EVH)
www.americanbankingnews.com - March 2 at 1:32 PM |
| Standard Life Aberdeen plc Buys New Holdings in Evolent Health Inc (EVH)
www.americanbankingnews.com - March 1 at 6:50 PM |
| Carillon Tower Advisers Inc. Acquires Shares of 945,560 Evolent Health Inc (EVH)
www.americanbankingnews.com - March 1 at 5:40 AM |
| Canaccord Genuity Lowers Evolent Health (EVH) Price Target to $24.00
www.americanbankingnews.com - February 28 at 5:52 PM |
| Evolent Health (EVH) PT Lowered to $20.00
www.americanbankingnews.com - February 28 at 4:12 PM |
| Evolent Health Announces Fourth Quarter and Full Year 2017 Results - PR Newswire (press release)
www.prnewswire.com - February 28 at 4:10 PM |
| Evolent Health Announces Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - February 28 at 10:31 AM |
| Evolent Health Inc (EVH) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 21 at 12:37 PM |
| -$0.04 EPS Expected for Evolent Health Inc (EVH) This Quarter
www.americanbankingnews.com - February 17 at 11:16 PM |
| Jefferies Group Comments on Evolent Health Inc's FY2017 Earnings (EVH)
www.americanbankingnews.com - February 15 at 7:56 AM |
| Jefferies Group Analysts Give Evolent Health (EVH) a $22.00 Price Target
www.americanbankingnews.com - February 13 at 3:10 PM |
| Evolent Health, Inc. to Release Fourth Quarter and Full Year 2017 ... - PR Newswire (press release)
www.prnewswire.com - February 9 at 3:26 PM |
| Evolent Health, Inc. to Release Fourth Quarter and Full Year 2017 Operating Results and Host Conference Call on Tuesday, February 27, 2018
finance.yahoo.com - February 9 at 3:26 PM |
| Evolent Health Inc (EVH) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - January 27 at 10:58 AM |
| William Blair Comments on Evolent Health Inc's FY2019 Earnings (EVH)
www.americanbankingnews.com - January 15 at 3:44 PM |
| KeyCorp Comments on Evolent Health Inc's Q1 2018 Earnings (EVH)
www.americanbankingnews.com - January 15 at 5:38 AM |
| Evolent Health Inc to Post Q4 2018 Earnings of ($0.01) Per Share, KeyCorp Forecasts (EVH)
www.americanbankingnews.com - January 12 at 8:02 PM |
| Brokers Offer Predictions for Evolent Health Inc's FY2017 Earnings (EVH)
www.americanbankingnews.com - January 8 at 2:28 AM |
| Evolent Health Inc Forecasted to Post Q3 2018 Earnings of ($0.01) Per Share (EVH)
www.americanbankingnews.com - January 5 at 12:32 PM |
| Evolent Health Sees Unusually Large Options Volume (EVH)
www.americanbankingnews.com - January 5 at 2:10 AM |
| Complete Genomics (GNOM) & Evolent Health (EVH) Financial Comparison
www.americanbankingnews.com - January 4 at 5:04 PM |
| Evolent Health Completes Acquisition of Assets from New Mexico ... - PR Newswire (press release)
www.prnewswire.com - January 2 at 11:27 PM |
| Evolent Health Completes Acquisition of Assets from New Mexico Health Connections
finance.yahoo.com - January 2 at 6:27 PM |
Evolent Health (NYSE:EVH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Evolent Health (NYSE:EVH) Income Statement, Balance Sheet and Cash Flow Statement
Evolent Health (NYSE EVH) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
